Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma
To evaluate the efficacy and safety of Anlotinib Hydrochloride Capsule combined with Best Supportive Therapy in the adjuvant treatment of patients with high-grade soft tissue sarcoma after operation, as compared with placebo combined with Best Supportive Therapy.
Soft Tissue Sarcoma Adult|High Grade Sarcoma
DRUG: Anlotinib Hydrochloride|DRUG: Placebo Oral Tablet
DFS, Disease Free Survival, 2 years|1-year and 2-year DFR, 1-year and 2-year disease-free survival rates, 2 years
OS, Overall Survival, 2 years|LRFS, Local Recurrence Free Survival, 2 years|DMFS, Distant Metastasis Free Survival, 2 years
To evaluate the efficacy and safety of Anlotinib Hydrochloride Capsule combined with Best Supportive Therapy in the adjuvant treatment of patients with high-grade soft tissue sarcoma after operation, as compared with placebo combined with Best Supportive Therapy.